A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects

NCT ID: NCT01638611

Last Updated: 2016-11-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-07-31
• Study Completion Date: 2012-09-30

Brief Summary

HIP2B is the stabilized form of the Human proIslet Peptide (HIP). Human proIslet Peptide is the human homolog of Islet Neogenesis Associated Protein (INGAP) peptide, which has shown signals of efficacy in type 1 and type 2 diabetes mellitus. In a mouse model of diabetes, repeat dose treatment with HIP results in new islet formation and improvement in blood glucose measurements.

HIP2B is being developed for the treatment of type 1 and type 2 diabetes mellitus.

The present clinical trial protocol proposes the first administration of HIP2B to humans with the goal of exploring the tolerability, safety and PK of HIP2B following subcutaneous single ascending doses.

Detailed Description

Primary Outcome:

To assess the tolerability and safety after subcutaneous single ascending doses of HIP2B in healthy male subjects. Adverse events including local injection site reactions/pain will be assessed during the study. Ongoing adverse events will be followed to resolution or for 30 days (whichever is sooner). Clinical laboratory evaluations including amylase and lipase will be reviewed. Vital signs and ECGs will be used to evaluate subject safety.

Secondary Outcome:

To assess the pharmacokinetics (including Cmax, AUClast, AUC0-∞, tmax, t1/2, tlag) in healthy male subjects after subcutaneous single ascending doses of HIP2B.

Conditions

Healthy

Keywords

Healthy male volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

HIP2B

Six subjects per dosing cohort will receive HIP2B

Group Type: ACTIVE_COMPARATOR

HIP2B

Intervention Type: DRUG

Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.

Placebo

Two subjects per dosing cohort will receive placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.

Interventions

HIP2B

Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.

Intervention Type: DRUG

Placebo

Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subject is a healthy, male, between 19 and 45 years inclusive.
• Subject's body weight is between 50.0 and 100.0 kg inclusive and body mass index (BMI) is between 18.0 and 31.6 kg/m2 inclusive.
• Subject is certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination) by the study doctor.
• Subject has normal vital signs after 10 minutes resting in supine position:

• 95 mmHg ≤ systolic blood pressure ≤ 140 mmHg
• 45 mmHg ≤ diastolic blood pressure ≤ 90 mmHg
• 40 beats per minute ≤ heart rate ≤100 beats per minute
• Subject has a normal standard 12-lead ECG after 10 minutes resting in supine position; 120 ms < PR < 220 ms, QRS < 120 ms, QTc ≤ 450 ms. Subject must be fasting.
• Laboratory parameters for the subject are within the normal range (or defined screening threshold for the Investigative site), unless the Investigator considers an abnormality to be not clinically significant for healthy subjects; however serum creatinine, alkaline phosphatase, hepatic enzymes (AST/ ALT, amylase, lipase, and fractional bilirubin (direct and indirect) should not exceed the upper laboratory norm).
• Male subjects must continue to use their approved contraceptive method and to refrain from donating semen for 30 days after participating in the study.
• The subject has given written informed consent prior to any study related procedures being performed.
• The subject is not under any administrative or legal supervision.

Exclusion Criteria

• The subject has any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteo-muscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
• The subject has frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).
• The subject has significant blood loss or blood donation, within 56 days prior to IP administration.
• The subject exhibits symptomatic hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in systolic blood pressure ≥ 20 mmHg within 3 minutes when changing from the supine to the standing position.
• The subject has the presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
• The subject has a history or presence of drug or alcohol abuse (alcohol consumption > 2 drinks per day).
• The subject smokes more than 5 cigarettes or equivalent per day, unable to stop smoking during the days the subject is confined or returning for study related testing.
• Excessive consumption of beverages with xanthine bases (> 4 8 ounce glasses per day) including energy drinks, weight loss drinks, protein mixes (i.e. for body building), etc.
• Any medication, herbal supplement or other natural products (including St John's Wort) within 14 days before the Day 1 visit or within 5 times the elimination half-life or pharmacodynamic half-life of that drug, whichever is longest; any vaccination within the last 28 days. This includes taking analgesics 2 days before Day 1 visit which will interfere with pain assessment.
• Any subject who, in the judgment of the Investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development.
• Any subject participating in another clinical trial of an investigational therapy (including placebo) within 30 days of screening or 5 half-lives of the study medication, whichever is longer.
• Any subject who cannot be contacted in case of emergency.
• Any subject who is the Investigator or any Sub-Investigator, Research Assistant, Pharmacist, Study Coordinator, or other staff thereof, directly involved in the conduct of the protocol.
• Any subject with a history or presence of any skin condition that would interfere with injection site assessments (including tattoos) and no umbilical piercings.
• Positive results on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
• Positive urine ethanol test.
• Any subject with either amylase or lipase levels above the upper laboratory norm
• Any subject with previous history of pancreatitis or known gallbladder disease (including gallstones and gallstone attacks; gallbladder removal will not exclude subject from participating).
• Any subject with prior exposure to INGAP peptide

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Celerion

INDUSTRY

Sponsor Role: collaborator

CureDM

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Scott Rasmussen, MD

Role: PRINCIPAL_INVESTIGATOR

Celerion

Locations

Celerion

Lincoln, Nebraska, United States

Countries

United States

Other Identifiers

TDU11656

Identifier Type: -

Identifier Source: org_study_id